Template:Dihydroergotamine: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0"; ! style="padding: 0 5px; font-size: 100%; background:#F8F8...")
 
No edit summary
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0";
{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[XXXXX|{{fontcolor|#6C7B8B|XXXXX}}]]'''''
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Dihydroergotamine|{{fontcolor|#6C7B8B|Dihydroergotamine}}]]'''''
|-
|-
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | ZZZZZ<sup>®</sup> FDA Package Insert
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | MIGRANAL (dihydroergotamine mesylate) spray<sup>®</sup> FDA Package Insert
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX indications and usage|Indications and Usage]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine indications and usage|Indications and Usage]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX dosage and administration|Dosage and Administration]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine dosage and administration|Dosage and Administration]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX dosage forms and strengths|Dosage Forms and Strengths]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine dosage forms and strengths|Dosage Forms and Strengths]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX contraindications|Contraindications]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine contraindications|Contraindications]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX warnings and precautions|Warnings and Precautions]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine warnings and precautions|Warnings and Precautions]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX adverse reactions|Adverse Reactions]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine adverse reactions|Adverse Reactions]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX drug interactions|Drug Interactions]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine drug interactions|Drug Interactions]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX use in specific populations|Use in Specific Populations]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine use in specific populations|Use in Specific Populations]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX overdosage|Overdosage]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine overdosage|Overdosage]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX description|Description]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine description|Description]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX clinical pharmacology|Clinical Pharmacology]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine clinical pharmacology|Clinical Pharmacology]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX nonclinical toxicology|Nonclinical Toxicology]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine nonclinical toxicology|Nonclinical Toxicology]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX clinical studies|Clinical Studies]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine clinical studies|Clinical Studies]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX how supplied storage and handling|How Supplied/Storage and Handling]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine how supplied storage and handling|How Supplied/Storage and Handling]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX patient counseling information|Patient Counseling Information]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine patient counseling information|Patient Counseling Information]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX labels and packages|Labels and Packages]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine labels and packages|Labels and Packages]]
|-
|-
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Clinical Trials on XXXXX
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Clinical Trials on Dihydroergotamine
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} ClinicalTrials.gov]
|-
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Dihydroergotamine|{{fontcolor|#6C7B8B|Dihydroergotamine}}]]'''''
|-
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | D.H.E. 45 (dihydroergotamine mesylate) injection, solution<sup>®</sup> FDA Package Insert
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine indications and usage|Indications and Usage]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine dosage and administration|Dosage and Administration]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine dosage forms and strengths|Dosage Forms and Strengths]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine contraindications|Contraindications]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine warnings and precautions|Warnings and Precautions]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine adverse reactions|Adverse Reactions]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine drug interactions|Drug Interactions]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine use in specific populations|Use in Specific Populations]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine overdosage|Overdosage]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine description|Description]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine clinical pharmacology|Clinical Pharmacology]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine nonclinical toxicology|Nonclinical Toxicology]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine clinical studies|Clinical Studies]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine how supplied storage and handling|How Supplied/Storage and Handling]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine patient counseling information|Patient Counseling Information]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine labels and packages|Labels and Packages]]
|-
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Clinical Trials on Dihydroergotamine
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} ClinicalTrials.gov]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} ClinicalTrials.gov]
|-
|-
|}
|}

Latest revision as of 22:06, 11 February 2014

Dihydroergotamine
MIGRANAL (dihydroergotamine mesylate) spray® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Dihydroergotamine
ClinicalTrials.gov
Dihydroergotamine
D.H.E. 45 (dihydroergotamine mesylate) injection, solution® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Dihydroergotamine
ClinicalTrials.gov
Retrieved from "https://www.wikidoc.org/index.php?title=Template:Dihydroergotamine&oldid=942435"